Medtronic Reports Strong Q2 FY26 Financial Results and Raises Guidance

Details

The company announced a significant 71% growth in its Cardiac Ablation Solutions, driven by its pulsed field ablation (PFA) portfolio. Medtronic also raised its full-year organic revenue growth guidance to approximately 5.5% and adjusted its diluted non-GAAP EPS guidance to a range of $5.62 to $5.66. The report highlights robust procedure volumes and market demand across its end markets.

Items reported

About Medtronic plc

Medtronic plc is a leading global healthcare technology company that designs, manufactures, and sells innovative medical devices and therapies used in various medical procedures. The primary function of Medtronic is to improve healthcare outcomes by providing advanced therapeutic solutions. Its extensive product portfolio includes cardiac and vascular devices, diabetes-related products, minimally invasive therapies, and neurosurgical technologies. Medtronic plays a vital role in the medical device industry, catering to cardiovascular treatment, advanced diabetes management, spinal and musculoskeletal therapy, and more. Notably, the company is renowned for its pacemaker technology and is a pivotal player in cardiac care. The company's innovations significantly impact the healthcare sector by enhancing the quality of life for patients worldwide and improving the effectiveness of medical treatments. As a key player in the medical device market, Medtronic is instrumental in setting industry standards and advancing medical technology through continuous research and development. Founded in 1949 and headquartered in Dublin, Ireland, Medtronic's global presence underscores its substantial contribution to the healthcare industry across various continents.